Plain-English translation of NCT07588438 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Obesity research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a year-long study testing tirzepatide, a medication given as a weekly injection, in Paraguay to see how well it helps people lose weight and manage diabetes in everyday life. The study includes two groups: adults with obesity who don't have diabetes, and adults with type 2 diabetes who may or may not have obesity. Researchers want to understand how the medication works in people living in Paraguay, taking into account local factors like diet and lifestyle.
While large clinical trials have shown this medication works well in controlled settings, doctors and patients in Paraguay need real-world data about how it performs in everyday conditions for their own communities. This study will provide that crucial local evidence and help doctors understand the medication's effects across different populations.
You likely qualify if…
You likely don't qualify if…
You will receive weekly injections of the medication at home or in a clinic for 52 weeks. The dose starts low and increases gradually over 4 weeks based on how you tolerate it and how your body responds. You'll also follow a structured nutrition plan with higher protein and lower carbohydrates (about 1,500 calories per day) to support weight loss or blood sugar improvement. Throughout the year, you'll have regular check-ins with the study team to monitor your progress, side effects, and overall health.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Paraguay